To date, the anti-CD147 monoclonal antibody drug Licartin has been used in clinical treatment of liver cancer, but the radioactive I130 contained in Licartin may have inconvenience and risk of radiation leakage in clinical application.366 Pseudolaric acid B (PAB), a recently reported natural product, was an antagonist of CD147, which could avoid the above-mentioned problems.367 So in 2020, Chen group reported the first CRBN-based CD147 degrader 200 (Fig. 55) derived from PAB. Here, BSG is linked to liver cancer.